CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

RS blendWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (10)

Name (Synonyms) Correlation
drug3410 placebo for clazakizumab Wiki 1.00
drug2917 Thromboprophylaxis Wiki 1.00
drug609 Candesartan Wiki 1.00
drug400 Best standard of care Wiki 1.00
drug3375 non-RAS blocking antihypertensives Wiki 1.00
drug660 Chloroquine or Hydroxychloroquine Wiki 0.58
drug1601 Lopinavir/Ritonavir Wiki 0.58
drug2458 Rivaroxaban Wiki 0.45
drug675 Clazakizumab Wiki 0.41
drug2122 Placebo Wiki 0.05

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Pilot Study to Evaluate the Gastrointestinal Response to Increasing Doses of a Resistant Starch Blend in Healthy Subjects

This study aims to test the hypothesis that a unique blend of resistant starches and fiber will promote gastrointestinal health, as measured by an increase in short-chain fatty acids and improvement in quality of life measures in conjunction with microbial community changes. This study specifically evaluates the impact on short-chain fatty acids and gut microbiota and the impact on quality of life from a resistant starch blend in healthy adult humans with occasional gastrointestinal distress.

NCT03983772 Quality of Life Health, Subjective Dietary Supplement: RS blend Other: Placebo

Primary Outcomes

Description: Concentration of total short-chain fatty acids, including valerate, isovalerate and isobutyrate, and individually-reported n-butyrate concentration as well as propionate and acetate % will be reported by Genova Diagnostics Report

Measure: Change in Concentration of short-chain fatty acids from baseline to each product intervention

Time: Baseline (2 week period) compared to each product completion period of 2 weeks

Secondary Outcomes

Description: Fecal frequency (time in hours between stools) will be evaluated for each time period and compared between baseline (2 week period) and product intervention period (each 2 week period)

Measure: Change in fecal frequency (hours between stools) from baseline at each intervention

Time: Baseline (2 week period) to end of product completion (2 week intervention for each dose and time combination)

Description: Response pattern score on PROMIS Scale v1.0 - GI Diarrhea will be compared between baseline and each intervention period

Measure: Change in Response pattern score for Frequency and Severity of Gastrointestinal Symptoms (PROMIS Scale v1.0 - GI Diarrhea 6a)

Time: Baseline (2 week period) to end of product completion (2 week intervention for each dose and time combination)

Description: Response pattern score on PROMIS Scale v1.0 - GI Constipation will be compared between baseline and each intervention period

Measure: Change in Response pattern score for Frequency and Severity of Gastrointestinal Symptoms (PROMIS Scale v1.0 - GI Constipation)

Time: Baseline (2 week period) to end of product completion (2 week intervention for each dose and time combination)

Description: Response pattern score on PROMIS Scale v1.0 - GI Gas and Bloating 13a 09-02-2016 will be compared between baseline and each intervention period

Measure: Change in Response pattern score for Frequency and Severity of Gastrointestinal Symptoms (PROMIS Scale v1.0 - GI Gas and Bloating 13a 09-02-2016)

Time: Baseline (2 week period) to end of product completion (2 week intervention for each dose and time combination)

No related HPO nodes (Using clinical trials)